Volume 12, Issue 2 (9-2026)
Caspian J Reprod Med 2026, 12(2): 1-3 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirabi P. From adherence to medication safety: Rethinking self-administered ovarian stimulation in IVF/ICSI care. Caspian J Reprod Med 2026; 12 (2) :1-3
URL: http://caspjrm.ir/article-1-304-en.html
URL: http://caspjrm.ir/article-1-304-en.html
Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran , Parvaneh.mirabi@gmail.com
Abstract: (341 Views)
Infertility affects approximately one in six people worldwide, making medication safety an essential component of high-quality fertility care. During IVF/ICSI, ovarian stimulation is largely managed at home, requiring patients to prepare, dose, store, and administer individualized medications, often following brief instruction. Available evidence suggests that medication-related difficulties may be more common than clinicians recognize, involving dosing, communication, dispensing, and injection device use. Importantly, medication adherence should not be equated with medication safety. A safer approach requires ongoing education, demonstration and teach-back, accessible professional support, and confidential, nonpunitive reporting of medication errors and near misses. Reframing self-administered ovarian stimulation as a system-level medication safety issue may help identify preventable risks, strengthen treatment support, and reduce avoidable disruptions to fertility care.
Type of Study: Letter to the editor |
Subject:
Reproductive Health
Received: 2026/09/4 | Accepted: 2026/09/28 | Published: 2026/09/29
Received: 2026/09/4 | Accepted: 2026/09/28 | Published: 2026/09/29
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
